Meeting Abstract


DOI :10.26650/JARHS2021-1133817   IUP :10.26650/JARHS2021-1133817    Full Text (PDF)

EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS

Ahmet DiricanSafiye AktaşTekincan AktaşAylin ErolÖzde GökbayrakHatice Efsun KolatanEfe Özgür SerinanZekiye Sultan AltunIşıl SomalıOsman Yılmaz

Objectives: Thymoquinone a bioactive component extracted from the seeds of Nigella sativa, has been proved to have antiinflammatory, antioxidant properties anti antitumor efficiency against breast, prostate, bladder, and renal cell cancer. We aimed to investigate the synergistic cytotoxic and apoptotic effects of thymoquinone in combination with nivolumab, an immuno-control inhibitor, and its mechanism in renal cell cancer models. Materials and Methods: In vitro studies: Caki-1 and Renca renal cancer cell lines with mononuclear cells were cocultured and thymoquinone and nivolumab effect were analyzed by MTT and Annexin V + PI. In vivo studies: Renal cell cancer model was provided by subcutaneous injection of RENCA cells to C57BL/6, male, 8 weeks old mice in four groups. Control group, thymoquinone (1,4,7,14days,20mg/kgIP), nivolumab administered (1,6,13days10mg/ kgIP), thymoquinone and nivolumab. Seven animals was randomized in each experimental group. Apoptosis, necrosis, CD4,CD8,C20,CD34,CD31,VEGF-A by immunohistochemistry, FGFR-1,PDGFRbeta,VEGFR-2,c-kit,RET,c-Met,AXL,Flt-3,TIE2, ICAM-1,VCAM-1 and E-selectin mRNA levels by quantitative real-timePCR were evaluated on tumor tissue. Liver, kidney, brain, lung and heart tissues was evaluated for side effects. Plasma biochemistry tests were performed. Statistical analysis was be performed with Mann-Whitney U test with p <0.05 value. Results: Thymoquinone showed antitumor effect in vitro and in vivo. It also showed increase in immune cell death of nivolumab. Tumor tissue showed prominent necrosis or complete response to therapy in combination group. Conclusions: We conclude that thymoquinone has antitumor effect on renal cell carcinoma and increases the effect of nivolumab immune, cell death effects. Besides, it does not have side effect on other organs whether alone or in combination. 


PDF View

References

    Citations

    Copy and paste a formatted citation or use one of the options to export in your chosen format


    EXPORT



    APA

    Dirican, A., Aktaş, S., Aktaş, T., Erol, A., Gökbayrak, Ö., Kolatan, H.E., Serinan, E.Ö., Altun, Z.S., Somalı, I., & Yılmaz, O. (2022). EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS. Journal of Advanced Research in Health Sciences, 5(1), 63-63. https://doi.org/10.26650/JARHS2021-1133817


    AMA

    Dirican A, Aktaş S, Aktaş T, Erol A, Gökbayrak Ö, Kolatan H E, Serinan E Ö, Altun Z S, Somalı I, Yılmaz O. EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS. Journal of Advanced Research in Health Sciences. 2022;5(1):63-63. https://doi.org/10.26650/JARHS2021-1133817


    ABNT

    Dirican, A.; Aktaş, S.; Aktaş, T.; Erol, A.; Gökbayrak, Ö.; Kolatan, H.E.; Serinan, E.Ö.; Altun, Z.S.; Somalı, I.; Yılmaz, O. EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 5, n. 1, p. 63-63, 2022.


    Chicago: Author-Date Style

    Dirican, Ahmet, and Safiye Aktaş and Tekincan Aktaş and Aylin Erol and Özde Gökbayrak and Hatice Efsun Kolatan and Efe Özgür Serinan and Zekiye Sultan Altun and Işıl Somalı and Osman Yılmaz. 2022. “EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS.” Journal of Advanced Research in Health Sciences 5, no. 1: 63-63. https://doi.org/10.26650/JARHS2021-1133817


    Chicago: Humanities Style

    Dirican, Ahmet, and Safiye Aktaş and Tekincan Aktaş and Aylin Erol and Özde Gökbayrak and Hatice Efsun Kolatan and Efe Özgür Serinan and Zekiye Sultan Altun and Işıl Somalı and Osman Yılmaz. EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS.” Journal of Advanced Research in Health Sciences 5, no. 1 (Feb. 2024): 63-63. https://doi.org/10.26650/JARHS2021-1133817


    Harvard: Australian Style

    Dirican, A & Aktaş, S & Aktaş, T & Erol, A & Gökbayrak, Ö & Kolatan, HE & Serinan, EÖ & Altun, ZS & Somalı, I & Yılmaz, O 2022, 'EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS', Journal of Advanced Research in Health Sciences, vol. 5, no. 1, pp. 63-63, viewed 24 Feb. 2024, https://doi.org/10.26650/JARHS2021-1133817


    Harvard: Author-Date Style

    Dirican, A. and Aktaş, S. and Aktaş, T. and Erol, A. and Gökbayrak, Ö. and Kolatan, H.E. and Serinan, E.Ö. and Altun, Z.S. and Somalı, I. and Yılmaz, O. (2022) ‘EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS’, Journal of Advanced Research in Health Sciences, 5(1), pp. 63-63. https://doi.org/10.26650/JARHS2021-1133817 (24 Feb. 2024).


    MLA

    Dirican, Ahmet, and Safiye Aktaş and Tekincan Aktaş and Aylin Erol and Özde Gökbayrak and Hatice Efsun Kolatan and Efe Özgür Serinan and Zekiye Sultan Altun and Işıl Somalı and Osman Yılmaz. EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS.” Journal of Advanced Research in Health Sciences, vol. 5, no. 1, 2022, pp. 63-63. [Database Container], https://doi.org/10.26650/JARHS2021-1133817


    Vancouver

    Dirican A, Aktaş S, Aktaş T, Erol A, Gökbayrak Ö, Kolatan HE, Serinan EÖ, Altun ZS, Somalı I, Yılmaz O. EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS. Journal of Advanced Research in Health Sciences [Internet]. 24 Feb. 2024 [cited 24 Feb. 2024];5(1):63-63. Available from: https://doi.org/10.26650/JARHS2021-1133817 doi: 10.26650/JARHS2021-1133817


    ISNAD

    Dirican, Ahmet - Aktaş, Safiye - Aktaş, Tekincan - Erol, Aylin - Gökbayrak, Özde - Kolatan, HaticeEfsun - Serinan, EfeÖzgür - Altun, ZekiyeSultan - Somalı, Işıl - Yılmaz, Osman. EFFECT OF THYMOQUINONE IN COMBINATION WITH NIVOLUMAB ON EXPERIMENTAL RENAL CELL CANCER MODELS”. Journal of Advanced Research in Health Sciences 5/1 (Feb. 2024): 63-63. https://doi.org/10.26650/JARHS2021-1133817



    TIMELINE


    Published Online09.08.2022

    LICENCE


    Attribution-NonCommercial (CC BY-NC)

    This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


    SHARE




    Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.